X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-12-16 | RNXT | Renovorx, Inc. | Agah Ramtin | Chief Medical Officer | P - Purchase | $0.85 | +12,000 | 778,460 | +2% | +$10,200 | ||||||
| DM | 2025-12-12 | IRON | Disc Medicine, Inc. | Bitterman Kevin | Dir | S - Sale+OE | $91.56 | -184,123 | 14,161 | -93% | -$16,858,639 | |||||
2025-12-15 | IRON | Disc Medicine, Inc. | Savage William Jacob | Chief Medical Officer | S - Sale | $91.22 | -13,093 | 75,702 | -15% | -$1,194,372 | ||||||
| DM | 2025-12-12 | MNKD | Mannkind Corp | Castagna Michael | CEO | S - Sale+OE | $6.00 | -42,116 | 2,504,792 | -2% | -$252,696 | |||||
| D | 2025-12-12 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $3.26 | -1,700 | 0 | -100% | -$5,541 | |||||
2025-12-12 | LGND | Ligand Pharmaceuticals Inc | Espinoza Octavio | CFO | S - Sale | $188.31 | -1,804 | 26,186 | -6% | -$339,711 | ||||||
2025-12-15 | SILO | Silo Pharma, Inc. | Weisblum Eric | CEO | P - Purchase | $0.42 | +5,000 | 216,932 | +2% | +$2,075 | ||||||
| D | 2025-12-15 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale+OE | $74.64 | -30,011 | 5,542,909 | -1% | -$2,239,902 | |||||
2025-12-12 | CLRB | Cellectar Biosciences, Inc. | Neis John | Dir | S - Sale | $3.70 | -198 | 10 | -95% | -$732 | ||||||
2025-12-15 | SXTP | 60 Degrees Pharmaceuticals, Inc. | Dow Geoffrey S | Pres, CEO | P - Purchase | $0.80 | +9,670 | 59,618 | +19% | +$7,759 | ||||||
| D | 2025-12-15 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $495.36 | -3,517 | 8,142 | -30% | -$1,742,193 | |||||
| DM | 2025-12-15 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $494.09 | -8,000 | 639,489 | -1% | -$3,952,689 | |||||
2025-12-15 | RAPP | Rapport Therapeutics, Inc. | Bredt David | Chief Scientific Officer | S - Sale | $30.02 | -8,500 | 392,642 | -2% | -$255,130 | ||||||
| D | 2025-12-12 | CPRX | Catalyst Pharmaceuticals, Inc. | Harper Molly | Dir | S - Sale+OE | $23.25 | -26,746 | 2,360 | -92% | -$621,920 | |||||
| D | 2025-12-15 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Pres, COO | S - Sale+OE | $18.68 | -12,500 | 189,141 | -6% | -$233,548 | |||||
2025-12-12 | ELAN | Elanco Animal Health Inc | Kurzius Lawrence Erik | Dir | P - Purchase | $21.30 | +10,000 | 131,773 | +8% | +$213,000 | ||||||
| D | 2025-12-15 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $496.30 | -22,500 | 2,648 | -89% | -$11,166,722 | |||||
| D | 2025-12-15 | UTHR | United Therapeutics Corp | Patusky Christopher | Dir | S - Sale+OE | $495.95 | -1,000 | 2,590 | -28% | -$495,954 | |||||
2025-12-12 | TYRA | Tyra Biosciences, Inc. | Bensen Daniel | Chief Discovery Officer | S - Sale | $22.64 | -8,000 | 162,981 | -5% | -$181,159 | ||||||
| D | 2025-12-16 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $61.24 | -2,200 | 138,552 | -2% | -$134,728 | |||||
2025-12-15 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, Chief Accounting Officer | S - Sale | $36.00 | -2,910 | 45,635 | -6% | -$104,760 | ||||||
| DM | 2025-12-12 | GALT | Galectin Therapeutics Inc | Shlevin Harold H. | Dir | S - Sale+OE | $6.28 | -28,210 | 30,829 | -48% | -$177,208 | |||||
2025-12-12 | PGEN | Precigen, Inc. | Kindler Jeffrey B | Dir | S - Sale | $3.63 | -235,467 | 110,603 | -68% | -$855,899 | ||||||
2025-12-12 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $40.00 | +87 | 381,795 | 0% | +$3,480 | ||||||
2025-12-12 | NATR | Natures Sunshine Products Inc | Yates Bryant J | EVP, Pres, Europe | S - Sale | $22.29 | -1,700 | 98,604 | -2% | -$37,893 | ||||||
| M | 2025-12-15 | ARWR | Arrowhead Pharmaceuticals, Inc. | Anzalone Christopher Richard | CEO | S - Sale | $67.00 | -184,298 | 3,916,957 | -4% | -$12,348,802 | |||||
| D | 2025-12-15 | RLMD | Relmada Therapeutics, Inc. | Traversa Sergio | CEO | P - Purchase | $4.12 | +27,500 | 1,300,000 | +2% | +$113,300 | |||||
| D | 2025-12-15 | RLMD | Relmada Therapeutics, Inc. | Shenouda Maged | CFO | P - Purchase | $4.12 | +11,665 | 800,000 | +1% | +$48,060 | |||||
| DM | 2025-12-11 | ROIV | Roivant Sciences Ltd. | Ramaswamy Vivek | 10% | S - Sale+OE | $21.89 | -3,103,745 | 47,011,612 | -6% | -$67,942,352 | |||||
2025-12-11 | VERA | Vera Therapeutics, Inc. | Enright Patrick G | Dir | P - Purchase | $42.50 | +5,882 | 5,400,094 | 0% | +$249,985 | ||||||
| DM | 2025-12-11 | CLYM | Climb Bio, Inc. | Ra Capital Management, L.P. | Dir, 10% | P - Purchase | $2.40 | +314,561 | 11,293,828 | +3% | +$754,737 | |||||
2025-12-15 | RZLT | Rezolute, Inc. | Evans Daron | CFO | P - Purchase | $1.77 | +45,000 | 512,900 | +10% | +$79,578 | ||||||
2025-12-15 | RZLT | Rezolute, Inc. | Elam Nevan C | CEO | P - Purchase | $1.59 | +32,000 | 641,119 | +5% | +$50,880 | ||||||
2025-12-15 | RZLT | Rezolute, Inc. | Karnawat Sunil Ratilal | Chief Commercial Officer | P - Purchase | $1.62 | +12,100 | 81,440 | +17% | +$19,599 | ||||||
| D | 2025-12-11 | IRON | Disc Medicine, Inc. | Quisel John D | CEO | S - Sale+OE | $93.05 | -40,000 | 171,828 | -19% | -$3,721,931 | |||||
| M | 2025-12-12 | EQ | Equillium, Inc. | Zedelmayer Christine | SVP, COO | S - Sale | $1.33 | -35,704 | 91,444 | -28% | -$47,486 | |||||
2025-12-12 | XERS | Xeris Biopharma Holdings, Inc. | Bormann-Kennedy Barbara-Jean Anne | Dir | S - Sale | $7.09 | -15,000 | 142,500 | -10% | -$106,415 | ||||||
2025-12-15 | ZNTL | Zentalis Pharmaceuticals, Inc. | Matrix Capital Management Company, LP | 10% | S - Sale | $1.33 | -7,500,000 | 6,459,973 | -54% | -$9,975,000 | ||||||
| M | 2025-12-11 | AMPH | Amphastar Pharmaceuticals, Inc. | Petersen Floyd F. | Dir | S - Sale | $25.82 | -4,163 | 71,368 | -6% | -$107,508 | |||||
2025-12-11 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $40.93 | -5,752 | 56,040 | -9% | -$235,405 | ||||||
2025-12-11 | ELAN | Elanco Animal Health Inc | Modi Rajeev A. | SEE REMARKS | P - Purchase | $21.33 | +4,500 | 123,082 | +4% | +$95,985 | ||||||
2025-12-11 | ELAN | Elanco Animal Health Inc | Vanhimbergen Robert M | EVP, CFO | P - Purchase | $21.64 | +6,950 | 124,233 | +6% | +$150,426 | ||||||
2025-12-11 | ELAN | Elanco Animal Health Inc | Simmons Jeffrey N | Pres, CEO, Dir | P - Purchase | $21.75 | +22,000 | 1,969,380 | +1% | +$478,496 | ||||||
| D | 2025-12-12 | OGEN | Oragenics Inc | Telling Fred | Dir | S - Sale+OE | $0.94 | -210 | 34,538 | -1% | -$198 | |||||
2025-12-11 | WVE | Wave Life Sciences Ltd. | Gsk Plc | 10% | P - Purchase | $19.00 | +1,470,000 | 18,245,691 | +9% | +$27,930,000 | ||||||
| D | 2025-12-11 | RYTM | Rhythm Pharmaceuticals, Inc. | Cramer Pamela J. | CHRO | S - Sale+OE | $111.00 | -3,350 | 20,814 | -14% | -$371,850 | |||||
2025-12-11 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cormorant Asset Management, LP | 10% | S - Sale | $11.46 | -30,029 | 2,344,971 | -1% | -$344,012 | ||||||
2025-12-11 | BMEA | Biomea Fusion, Inc. | Erdtmann Rainer M | See Remarks | P - Purchase | $1.43 | +30,000 | 2,572,820 | +1% | +$42,999 | ||||||
2025-12-11 | AARD | Aardvark Therapeutics, Inc. | Sun Nelson | CFO | P - Purchase | $14.40 | +3,000 | 108,484 | +3% | +$43,200 | ||||||
2025-12-11 | AARD | Aardvark Therapeutics, Inc. | Lee Tien-Li | CEO, 10% | P - Purchase | $14.49 | +7,000 | 3,025,641 | 0% | +$101,395 | ||||||
2025-12-12 | TTRX | Turn Therapeutics Inc. | Chaudhary Zuraiz | See Remarks | P - Purchase | $3.50 | +2,500 | 12,500 | +25% | +$8,750 | ||||||
| M | 2025-12-10 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $1.07 | -82,971 | 2,890,128 | -3% | -$88,587 | |||||
2025-12-10 | CYRX | Cryoport, Inc. | Mandalam Ramkumar | Dir | S - Sale | $9.99 | -11,570 | 80,758 | -13% | -$115,540 | ||||||
2025-12-12 | IMVT | Immunovant, Inc. | Roivant Sciences Ltd. | Dir, 10% | P - Purchase | $21.00 | +16,666,666 | 113,317,007 | +17% | +$349,999,986 | ||||||
| M | 2025-12-10 | VSTM | Verastem, Inc. | Paterson Dan | Pres, CEO | S - Sale | $10.04 | -4,000 | 410,818 | -1% | -$40,140 | |||||
| DM | 2025-12-10 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $321.64 | -664 | 223,106 | 0% | -$213,569 | |||||
| D | 2025-12-10 | MDGL | Madrigal Pharmaceuticals, Inc. | Friedman Paul A | Dir | S - Sale+OE | $552.18 | -24,800 | 842,704 | -3% | -$13,694,158 | |||||
| D | 2025-12-10 | MDGL | Madrigal Pharmaceuticals, Inc. | Taub Rebecca | Dir | S - Sale+OE | $552.15 | -18,650 | 1,111,129 | -2% | -$10,297,573 | |||||
2025-12-11 | UTHR | United Therapeutics Corp | Malcolm Jan | Dir | S - Sale | $482.98 | -50 | 470 | -10% | -$24,149 | ||||||
| D | 2025-12-11 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $484.67 | -11,000 | 36,781 | -23% | -$5,331,316 | |||||
| DM | 2025-12-11 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $487.33 | -8,000 | 639,489 | -1% | -$3,898,662 | |||||
| D | 2025-12-11 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $3.24 | -3,555 | 0 | -100% | -$11,520 | |||||
| M | 2025-12-10 | SXTP | 60 Degrees Pharmaceuticals, Inc. | Dow Geoffrey S | Pres, CEO | P - Purchase | $0.94 | +12,963 | 49,948 | +35% | +$12,204 | |||||
2025-12-11 | FBLG | Fibrobiologics, Inc. | Garcia Ruben A | GC | P - Purchase | $0.34 | +140,000 | 140,000 | New | +$47,600 | ||||||
| DM | 2025-12-09 | PCRX | Pacira Biosciences, Inc. | Cross Shawn | CFO | S - Sale+OE | $25.07 | -25,000 | 56,250 | -31% | -$626,751 | |||||
| D | 2025-12-09 | ROIV | Roivant Sciences Ltd. | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $20.85 | -200,000 | 1,497,908 | -12% | -$4,170,000 | |||||
| M | 2025-08-21 | GNLX | Genelux Corp | Yu Yong | SVP, Clinical Development | S - Sale | $3.82 | -4,192 | 145,844 | -3% | -$16,032 | |||||
| M | 2025-08-21 | GNLX | Genelux Corp | Zindrick Thomas | Pres, CEO | S - Sale | $3.86 | -17,182 | 538,431 | -3% | -$66,370 | |||||
| M | 2025-08-21 | GNLX | Genelux Corp | Cappello Joseph | Chief Technical Officer | S - Sale | $3.88 | -3,706 | 156,060 | -2% | -$14,361 | |||||
2025-12-09 | IRD | Opus Genetics, Inc. | Foundation Fighting Blindness Retinal Degeneration Fund | See Remarks | S - Sale | $2.15 | -4,000,000 | 5,492,171 | -42% | -$8,600,000 | ||||||
2025-12-09 | JAZZ | Jazz Pharmaceuticals Plc | Henderson Mary Elizabeth | SVP, Technical Operations | S - Sale | $169.51 | -2,238 | 19,508 | -10% | -$379,366 | ||||||
| D | 2025-12-09 | BIOA | Bioage Labs, Inc. | Rubin Paul D | Chief Medical Officer | S - Sale+OE | $12.00 | -18,000 | 0 | -100% | -$216,000 | |||||
| DM | 2025-12-09 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $3.33 | -1,245 | 0 | -100% | -$4,149 | |||||
| D | 2025-12-09 | TEVA | Teva Pharmaceutical Industries Ltd | Daniell Richard | EVP, European Commercial | S - Sale+OE | $28.68 | -115,468 | 48,384 | -70% | -$3,311,126 | |||||
| D | 2025-12-09 | TEVA | Teva Pharmaceutical Industries Ltd | Sabag Mark | See "Remarks" | S - Sale+OE | $28.73 | -216,892 | 52,828 | -80% | -$6,230,754 | |||||
2025-12-10 | RARE | Ultragenyx Pharmaceutical Inc. | Horn Howard | CFO | S - Sale | $36.38 | -3,081 | 95,146 | -3% | -$112,087 | ||||||
| D | 2025-12-09 | CRMD | Cormedix Inc. | Dillione Janet | Dir | S - Sale+OE | $12.00 | -34,000 | 48,473 | -41% | -$408,000 | |||||
| D | 2025-12-10 | APRE | Aprea Therapeutics, Inc. | Duey Marc | Dir | P - Purchase | $1.17 | +21,459 | 256,757 | +9% | +$25,000 | |||||
| D | 2025-12-10 | APRE | Aprea Therapeutics, Inc. | Hamill John P. | SrVP, CFO, Prin Fin, Acct Ofcr | P - Purchase | $1.17 | +5,000 | 27,733 | +22% | +$5,825 | |||||
| D | 2025-12-08 | WVE | Wave Life Sciences Ltd. | Rawcliffe Adrian | Dir | S - Sale+OE | $15.00 | -42,000 | 12,700 | -77% | -$630,000 | |||||
| D | 2025-12-08 | WVE | Wave Life Sciences Ltd. | Wagner Heidi L | Dir | S - Sale+OE | $13.50 | -14,000 | 44,930 | -24% | -$189,000 | |||||
| D | 2025-12-08 | WVE | Wave Life Sciences Ltd. | Henry Christian O | Dir | S - Sale+OE | $14.65 | -93,445 | 12,700 | -88% | -$1,369,324 | |||||
| D | 2025-12-08 | WVE | Wave Life Sciences Ltd. | Tan Aik Na | Dir | S - Sale+OE | $13.58 | -134,218 | 25,400 | -84% | -$1,823,159 | |||||
2025-12-08 | WVE | Wave Life Sciences Ltd. | Verdine Gregory L. | Dir | S - Sale | $13.47 | -20,000 | 275,217 | -7% | -$269,461 | ||||||
| D | 2025-12-08 | WVE | Wave Life Sciences Ltd. | Francis Chris | See Remarks | S - Sale+OE | $14.57 | -441,031 | 25,000 | -95% | -$6,427,085 | |||||
| DM | 2025-12-08 | WVE | Wave Life Sciences Ltd. | Moran Kyle | CFO | S - Sale+OE | $15.78 | -260,036 | 90,365 | -74% | -$4,103,979 | |||||
2025-12-08 | WVE | Wave Life Sciences Ltd. | Corrigan Mark | Dir | S - Sale | $13.48 | -16,115 | 28,815 | -36% | -$217,297 | ||||||
2025-12-09 | CRMD | Cormedix Inc. | Lefkowitz Steven W | Dir | S - Sale | $11.88 | -40,000 | 112,650 | -26% | -$475,200 | ||||||
2025-12-08 | XCUR | Exicure, Inc. | Sangsangin Investment & Securities Co., Ltd. | 10% | S - Sale | $8.71 | -433,332 | 0 | -100% | -$3,774,322 | ||||||
2025-12-10 | IMMX | Immix Biopharma, Inc. | Rachman Ilya M | CEO, COB | P - Purchase | $6.67 | +746 | 1,141,683 | 0% | +$4,976 | ||||||
| DM | 2025-12-08 | TENX | Tenax Therapeutics, Inc. | Rich Stuart | Chief Medical Officer | P - Purchase | $10.16 | +5,000 | 12,654 | +65% | +$50,793 | |||||
| D | 2025-12-10 | IMMX | Immix Biopharma, Inc. | Morris Gabriel S | CFO | P - Purchase | $6.58 | +770 | 742,414 | 0% | +$5,067 | |||||
| D | 2025-11-26 | MRUS | Merus N.V. | Shuman Harry | VP Controller, PAO | S - Sale+OE | $96.10 | -1,700 | 11,002 | -13% | -$163,370 | |||||
2025-12-08 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $21.02 | -6,663 | 263,311 | -2% | -$140,073 | ||||||
| D | 2025-12-08 | KNSA | Kiniksa Pharmaceuticals International, Plc | Ragosa Mark | CFO | S - Sale+OE | $41.49 | -42,841 | 31,086 | -58% | -$1,777,473 | |||||
| D | 2025-12-09 | SNSE | Sensei Biotherapeutics, Inc. | Cambrian Biopharma Inc | 10% | S - Sale+OE | $8.25 | -6,612 | 155,142 | -4% | -$54,575 | |||||
2025-12-09 | UTHR | United Therapeutics Corp | Mesa Nilda | Dir | S - Sale | $481.63 | -187 | 5,286 | -3% | -$90,065 | ||||||
| DM | 2025-12-09 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $479.17 | -8,000 | 639,489 | -1% | -$3,833,374 | |||||
| DM | 2025-12-08 | SNSE | Sensei Biotherapeutics, Inc. | Peyer James | See remarks below, 10% | S - Sale+OE | $8.25 | -6,612 | 155,142 | -4% | -$54,575 | |||||
2025-12-08 | FULC | Fulcrum Therapeutics, Inc. | Ra Capital Management, L.P. | 10% | S - Sale | $13.98 | -4,175,139 | 6,053,960 | -41% | -$58,377,021 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |